10-Q: Agentix Corp. Reports Q3 2025 Results: Losses Continue Amidst Going Concern Concerns

Agentix Corp.'s Q3 2025 report reveals ongoing losses and negative cash flow, raising substantial doubt about the company's ability to continue as a going concern.

Summary

• Agentix Corp. reported its financial results for the quarter ended December 31, 2024.
• The company is a clinical-stage biotechnology company focused on developing therapeutic agents for metabolic diseases.
• Agentix Corp. is facing significant financial challenges, including an accumulated deficit and negative cash flows from operating activities.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company recorded no revenues for the three and nine months ended December 31, 2024 and 2023.
• Net loss for the three months ended December 31, 2024 was $(143,894) compared to a net income of $6,374 for the same period in 2023.
• Net loss for the nine months ended December 31, 2024 was $(385,280) compared to $(582,156) for the same period in 2023.
• Total assets as of December 31, 2024 were $154,111, while total liabilities were $3,070,854, resulting in a stockholders' deficit of $(2,916,743).
• The company's cash position as of December 31, 2024 was $8,273.
• The company owes vendors and related parties $3,022,359 as of December 31, 2024.
• The company will need to raise funds to complete its plan of operation and fund its ongoing operational expenses for the next 12 months.

Sentiment

Score: 2

Explanation: The document paints a concerning picture of Agentix Corp.'s financial health, with significant losses, a weak cash position, and doubts about its ability to continue as a going concern. The need for a capital raise further underscores the company's precarious situation.

Positives

• The net loss for the nine months ended December 31, 2024 decreased to $(385,280) compared to $(582,156) for the same period in 2023.
• Professional fees decreased by $117,405 for the nine months ended December 31, 2024 as compared to the same period in 2023.
• General and administrative expenses decreased by $272,995 for the nine months ended December 31, 2024 as compared to the same period in 2023.

Negatives

• Agentix Corp. is facing substantial doubt about its ability to continue as a going concern.
• The company reported no revenues for the three and nine months ended December 31, 2024 and 2023.
• The company has a significant accumulated deficit and negative working capital.
• The company's cash balance as of December 31, 2024 was only $8,273.
• The company owes vendors and related parties a substantial amount of $3,022,359 as of December 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional funds.
• Failure to secure additional financing could lead to the failure of the business.
• Existing shareholders may experience dilution if the company completes an equity financing.
• The terms of any debt financing may not be favorable to existing shareholders.
• The company's disclosure controls and procedures were not effective as of December 31, 2024.

Future Outlook

The company will need to raise funds to complete its plan of operation and fund its ongoing operational expenses for the next 12 months, likely through equity or debt financing.

Management Comments

• Management believes that the company's cash position is not sufficient to support its daily operations.
• Management acknowledges the need to raise funds to complete the plan of operation and fund ongoing operational expenses.
• Mr. Huda concluded as of the evaluation date that our disclosure controls and procedures were not effective as of December 31, 2024.

Industry Context

As a clinical-stage biotechnology company, Agentix Corp.'s financial struggles are not uncommon, as these companies often require significant capital investment and face high risks in drug development.

Comparison to Industry Standards

• It is difficult to compare Agentix Corp.'s results to industry standards without knowing the specific stage of development and therapeutic focus.
• Many clinical-stage biotech companies operate at a loss for extended periods, relying on venture capital or strategic partnerships for funding.
• A key metric for comparison would be the company's cash burn rate relative to its peers and the stage of its clinical programs.
• Comparisons to companies like Galectin Therapeutics or Viking Therapeutics, which are also focused on metabolic diseases, could provide some context, but a detailed analysis of their financial statements and clinical pipelines would be necessary.

Related Party Transactions

• SBS Management LLC, a company controlled by Mr. Scott Stevens, received management consulting fees and made advancement of funds to the Company.
• Grays Peak Capital made advances to the Company to cover certain operating expenses.
• The Company entered into two separate Mezzanine Secured Notes with Grays Peak Private Credit LLC.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises capital through equity financing.
• Employees' jobs are at risk if the company is unable to continue as a going concern.
• Creditors face the risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company needs to secure additional financing to continue its operations.
• The company needs to improve its disclosure controls and procedures.
• The company needs to execute its business plan and generate sufficient revenue.

Key Dates

Keywords

financial results, biotechnology, going concern, Agentix Corp, metabolic disease, liquidity, financing, losses, cash flow